End-of-day quote
Shanghai S.E.
23:00:00 26/06/2024 BST
|
5-day change
|
1st Jan Change
|
37.4
CNY
|
-5.08%
|
|
-8.80%
|
-21.84%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
14,959
|
16,030
|
19,530
|
15,545
|
-
|
-
|
Enterprise Value (EV)
1 |
14,959
|
16,030
|
19,530
|
15,545
|
15,545
|
15,545
|
P/E ratio
|
-19.9
x
|
-21.6
x
|
-17.6
x
|
-15.3
x
|
-22.2
x
|
-94.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,454
x
|
-
|
214
x
|
38.7
x
|
17.5
x
|
8.17
x
|
EV / Revenue
|
1,454
x
|
-
|
214
x
|
38.7
x
|
17.5
x
|
8.17
x
|
EV / EBITDA
|
-
|
-23.2
x
|
-18.4
x
|
-15.9
x
|
-24.5
x
|
-116
x
|
EV / FCF
|
-
|
-23.7
x
|
-19.5
x
|
-12.6
x
|
-19.6
x
|
274
x
|
FCF Yield
|
-
|
-4.22%
|
-5.12%
|
-7.95%
|
-5.11%
|
0.36%
|
Price to Book
|
6.07
x
|
9.11
x
|
23.5
x
|
-95.1
x
|
-18
x
|
-16.7
x
|
Nbr of stocks (in thousands)
|
404,183
|
407,160
|
408,151
|
415,653
|
-
|
-
|
Reference price
2 |
37.01
|
39.37
|
47.85
|
37.40
|
37.40
|
37.40
|
Announcement Date
|
25/02/22
|
27/02/23
|
24/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
10.29
|
-
|
91.29
|
401.3
|
886.3
|
1,903
|
EBITDA
1 |
-
|
-
|
-692.4
|
-1,060
|
-979
|
-634.5
|
-134
|
EBIT
1 |
-
|
-669.9
|
-735.7
|
-1,108
|
-1,014
|
-699.3
|
-164.5
|
Operating Margin
|
-
|
-6,512.85%
|
-
|
-1,213.31%
|
-252.66%
|
-78.9%
|
-8.64%
|
Earnings before Tax (EBT)
1 |
-
|
-669.9
|
-735.7
|
-1,108
|
-1,014
|
-699.3
|
-164.5
|
Net income
1 |
-586.6
|
-669.9
|
-736
|
-1,108
|
-1,014
|
-699.3
|
-164.5
|
Net margin
|
-
|
-6,512.85%
|
-
|
-1,213.42%
|
-252.66%
|
-78.9%
|
-8.64%
|
EPS
2 |
-1.630
|
-1.860
|
-1.820
|
-2.720
|
-2.440
|
-1.683
|
-0.3950
|
Free Cash Flow
1 |
-
|
-
|
-677.2
|
-1,000
|
-1,235
|
-794.8
|
56.73
|
FCF margin
|
-
|
-
|
-
|
-1,095.44%
|
-307.78%
|
-89.67%
|
2.98%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/11/21
|
25/02/22
|
27/02/23
|
24/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-677
|
-1,000
|
-1,235
|
-795
|
56.7
|
ROE (net income / shareholders' equity)
|
-
|
-37.8%
|
-34.9%
|
-85%
|
-426%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-30.5%
|
-62.8%
|
-73%
|
-44.6%
|
-15.1%
|
Assets
1 |
-
|
-
|
2,414
|
1,764
|
1,390
|
1,570
|
1,089
|
Book Value Per Share
2 |
-
|
6.090
|
4.320
|
2.040
|
-0.3900
|
-2.080
|
-2.240
|
Cash Flow per Share
2 |
-
|
-1.370
|
-1.480
|
-2.380
|
-2.630
|
-1.650
|
-
|
Capex
1 |
-
|
-
|
73.8
|
32.1
|
104
|
117
|
76.5
|
Capex / Sales
|
-
|
-
|
-
|
35.19%
|
25.98%
|
13.14%
|
4.02%
|
Announcement Date
|
22/11/21
|
25/02/22
|
27/02/23
|
24/02/24
|
-
|
-
|
-
|
Last Close Price
37.4
CNY Average target price
54
CNY Spread / Average Target +44.39% Consensus |
1st Jan change
|
Capi.
|
---|
| -21.84% | 2.25B | | +16.13% | 122B | | +19.65% | 115B | | +21.22% | 26.64B | | -23.84% | 19.91B | | -17.47% | 16.32B | | -45.95% | 15.52B | | -19.28% | 15.49B | | +63.81% | 14.83B | | +1.94% | 13.67B |
Bio Therapeutic Drugs
|